What To Expect From JNJ Stock In 2025?
Portfolio Pulse from
Johnson & Johnson (JNJ) stock underperformed in 2024, losing 7% compared to the S&P 500's 23% gain. Other pharmaceutical companies like Eli Lilly and AbbVie saw significant stock increases.
January 10, 2025 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Johnson & Johnson's stock fell by 7% in 2024, underperforming the S&P 500 and other pharmaceutical companies like Eli Lilly and AbbVie.
JNJ's stock performance in 2024 was negative, losing 7% while the S&P 500 gained 23%. This underperformance compared to peers like Eli Lilly and AbbVie suggests potential investor concerns or challenges specific to JNJ.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100